Search

Displaying results 6791 - 6800 of 10000 in total
  1. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.

    Synonyms: NBOH-2C-CN, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
  2. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose

  3. Drug

    Bumadizone

    go.drugbank.com/drugs/DB13286
    Approved

    Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis

  4. Drug

    OMS-103HP

    go.drugbank.com/drugs/DB05303
    Investigational

    OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.

  5. Drug

    Medetomidine

    go.drugbank.com/drugs/DB11428
    ExperimentalVet approved

    In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. … Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma.

  6. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to [DB00545] and [DB01400].

  7. Drug

    Cefpirome

    go.drugbank.com/drugs/DB13682
    Approved

    Cefpirome is a β-lactam or cephalosporin.

  8. Drug

    Paquinimod

    go.drugbank.com/drugs/DB13118
    Investigational

    The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.

  9. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    There have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.

  10. Drug

    Ditiocarb

    go.drugbank.com/drugs/DB02520
    Investigational

    A chelating agent that has been used to mobilize toxic metals from the tissues of man and experimental animals. It is the main metabolite of DISULFIRAM.

    Categories: Compounds used in a research, industrial, or household setting